ProCE Banner Activity

关于 ART 期间不良事件的新见解和对治疗的影响:2021 年秋季的关键数据

Text Module
从 2021 年秋季 HIV 会议的新数据中获得专家见解,这些数据扩大了我们对与 ART 相关的不良事件的理解,特别强调了体重增加、代谢并发症和怀孕问题。

Released: February 01, 2022

Expiration: January 31, 2023

Share

Faculty

Gregory Huhn

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

教育资助金由以下机构提供:

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Target Audience

该计划适用于照顾 HIV 感染者的医生、注册护士、药剂师和其他医疗保健提供者。

Learning Objectives

Upon completion of this activity, participants should be able to:
  • 针对接受病毒学抑制治疗方案时发生不良事件或耐受性差的患者制定恰当的 ART 修改策略
  • 制定旨在避免禁忌症和尽量减少不良事件的策略以优化针对特殊人群的 HIV 医疗护理工作

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Gregory Huhn(医学博士,MPHTM)透露,他已收到 Gilead Sciences、Janssen、Lilly 和 ViiV 的研究支持资金以及 Gilead Sciences、Janssen 和 ViiV 的咨询费。

Staff Disclosure

Staff

Jessica L. Adams, PharmD, AAHIVE

Scientific Director, Infectious Diseases
Clinical Care Options
New York, United States

Jessica Adams,药学博士,BCPS,AAHIVP,没有要报告的相关利益冲突。

Katherine L. DeYoung, PhD

Editorial Contributor

Katherine DeYoung 博士没有要报告的相关利益冲突。

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons(哲学博士)没有要报告的相关利益冲突。

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz(理学硕士、ELS)没有要报告的相关利益冲突。

Julie Skowronski, FNP-BC

Julie Skowronski,FNP-BC,没有相关的利益冲突要报告。

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Goal


这项活动的目标是提高学习者在为 HIV 感染患者选择或调整个体化 ART 方案时应用有关 ART 安全性和耐受性的最新数据的能力。